Former Teva CEO Israel Makov On Hurdles For Innovative Drug Companies Entering Generics Space: An Interview With PharmAsia News
This article was originally published in PharmAsia News
Executive Summary
Israel Makov's four years as generic giant Teva's chief executive officer, until 2007, were the most outstanding for the company as it took up patent challenges on billion dollar brands while making deep inroads into the innovation domain with its multiple sclerosis brand Copaxone. Makov now heads medical devices company Given Imaging, but is still very closely following movements in the global generic drug industry. Makov met with PharmAsia News' India bureau chief on the sidelines of the recent BioPharma Asia conference in Singapore to speak about his past experiences and what lies ahead for the industry - from generic chemical drugs to biosimilars.
You may also be interested in...
Global Transformation? Sun Pharma Names Former Teva CEO Israel Makov As Chairman
Experts say the Indian pharma’s strategy may be to drive high growth in RoW markets and enable a transition to professional management.
Knowledge Synergies Between Small Innovators Can Accelerate Drug Development, Experts Speak Out
SINGAPORE - It may sound too idealistic but Israel Makov, Teva's former chief executive, believes the present drought of late-stage pipeline drugs can be filled if smaller companies doing research in "silos" share their specialized insights and form single entities to develop future drugs
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).